Previous close | 0.8000 |
Open | 0.6000 |
Bid | 0.7900 |
Ask | 0.9600 |
Strike | 42.50 |
Expiry date | 2025-06-20 |
Day's range | 0.6000 - 0.8000 |
Contract range | N/A |
Volume | |
Open interest | 38 |
Gilead Sciences ( NASDAQ:GILD ) First Quarter 2024 Results Key Financial Results Revenue: US$6.69b (up 5.3% from 1Q...
Gilead stock pared its gains Friday after beating first-quarter sales forecasts on the back of its Covid treatment, Veklury.
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.